Patients Sue GLP-1 Makers Over Sudden Loss of Vision: What the Lawsuits Claim and What the Evidence Shows

If you take Ozempic, Wegovy, Zepbound or Mounjaro, or you’re thinking about starting one, this week’s headlines probably gave you pause. Patients are suing Novo Nordisk and Eli Lilly, saying they suddenly lost vision while on these drugs and that the companies failed to warn them. NewsNation

The story is serious, but it’s also more nuanced than the headlines make it sound. Below, we walk through what the lawsuits allege, what the eye condition at the center of them actually is, what the research says so far, and what a sensible next step looks like if you’re on one of these medications.

Stay Connected with The Cheek Filler

The Short Version

The claim: Patients say GLP-1 drugs caused a rare condition called NAION, and that the manufacturers should have warned them.
The condition: NAION causes sudden vision loss, usually in one eye, and there is no proven treatment.
The science: Several large studies found a higher risk, others didn’t, and no study has proven cause and effect.
The regulators: Europe, the UK and Australia have acted. The US FDA is still reviewing the question.
Your move: Don’t stop your medication on your own. Learn the warning signs, and talk to your doctor if you have risk factors.

What the GLP-1 Vision Loss Lawsuits Actually Say

Who Is Being Sued

Novo Nordisk, which makes Wegovy and Ozempic, and Eli Lilly, which makes Zepbound, both face suits from patients who say they lost vision while taking the drugs. Plaintiffs’ claims also reach Mounjaro and Trulicity, though Novo has drawn most of the litigation so far. NewsNation Review of Optometry

The numbers keep moving. Thousands of suits have been filed against the drugmakers overall, including claims of gastrointestinal injury, and hundreds specifically allege NAION damage. In federal court, the vision cases have their own docket: MDL 3163, created in December 2025 to consolidate NAION claims, sits before Judge Karen S. Marston in the Eastern District of Pennsylvania. The judicial panel’s September 1, 2026 statistics showed 216 actions pending. GLP-1 lawsuits allege drugs caused permanent eye damage and vision loss +2

The Failure-to-Warn Argument

Notice what the plaintiffs are not mainly arguing. They aren’t saying these drugs should never have reached the market. Their core argument is about information. The lawsuits say the drugmakers should have known about the potential side effect and told patients, yet it isn’t on US warning labels, while some updated labels in other countries do include it. WCAX

That gap between US and overseas labeling is the backbone of many of the cases.

The Human Stories Behind the Filings

Behind the legal language are people. Diane Wirth, 66, a nurse practitioner in rural Georgia, was taking Wegovy for weight loss when she suddenly lost vision in her right eye. It was her only symptom. Her attorney says his firm represents at least 150 people diagnosed with NAION after using various GLP-1 drugs for weight loss or type 2 diabetes. NBC Los AngelesNBC Los Angeles

USA Today reported a harder case, too. A 63-year-old man started Ozempic for diabetes in 2023 and woke up four months later with vision loss in one eye. Not knowing the cause, he kept taking it, lost sight in the other eye in 2024, and is now legally blind. Whatever the courts ultimately decide, that story carries a practical lesson about acting fast when your vision changes, which we come back to below. AZFamily

How the Drugmakers Are Responding

Both companies are pushing back. Novo Nordisk told NBC News it hasn’t seen NAION safety signals in its randomized clinical trials and believes the lawsuits are without merit. Eli Lilly says patient safety is its top priority and that it will keep reviewing data, including anything on eye-related issues. NBC Los AngelesNBC Los Angeles

What Is NAION (Nonarteritic Anterior Ischemic Optic Neuropathy)?

NAION is short for nonarteritic anterior ischemic optic neuropathy. It happens when blood flow to the optic nerve drops, and it can cause sudden vision loss in one or both eyes. Doctors often compare it to a stroke of the optic nerve. That’s a useful picture, but it’s an analogy rather than a literal diagnosis. WCAX

The hard part is what comes after. Dr. Douglas Lazzaro, an ophthalmologist at NYU Langone Health, told Fox News Digital that there’s no treatment, so the vision loss can be profound. Fox News

Symptoms to Watch For

NAION typically causes sudden, painless vision loss in one eye. Other signs can include blurry or dim vision, loss of side vision and fading color perception, and symptoms often show up first thing in the morning. Fox News

Because it doesn’t hurt, it’s easy to dismiss at first. People rub their eyes, assume it’s fatigue, and wait. Please don’t.

Who Is Already at Higher Risk?

Here’s the wrinkle that makes this so hard to untangle. The biggest known risk factors for NAION include age, diabetes, high blood pressure, high cholesterol, obstructive sleep apnea and smoking. Many people on GLP-1s share those exact conditions. Fox News

Being over 50
Type 2 diabetes
High blood pressure or high cholesterol
Sleep apnea
Smoking
A crowded optic nerve structure, sometimes called a “disc at risk,” which an eye doctor can spot in an exam

What the Research Says: A Real Signal, Not a Settled Answer

Studies Pointing to a Link

The concern began in 2024. A possible signal emerged from a Boston health system that year, was reported at a major eye-research meeting, and was then published in JAMA Ophthalmology. That study reported a hazard ratio of 4.28 for people with type 2 diabetes on semaglutide and 7.64 for people using it for weight management, compared with patients on other medications. Both figures are large but come from one health system’s records. Review of Optometry

Other data followed:

Denmark: A nationwide study of 424,152 people with type 2 diabetes found a hazard ratio of 2.19 for NAION among those on once-weekly semaglutide. nih
Denmark and Norway combined: A pooled analysis reported a hazard ratio of 2.81, with about 1.41 extra cases per 10,000 person-years. PubMed Central
Meta-analysis: One pooled review found a hazard ratio of 2.62 for semaglutide versus control medications. ScienceDirect

Put those in context. A doubled risk sounds dramatic, but it’s doubling something rare. The European regulator’s safety committee estimated roughly one additional NAION case per 10,000 person-years of treatment in adults with type 2 diabetes. Baller Alert

Why Some Experts Aren’t Convinced

The picture isn’t one-sided. Other large database studies found no statistically significant increase in NAION risk among semaglutide users. NAION also has no diagnosis code of its own, which makes tracking difficult. Then there’s the overlap problem covered above: people on GLP-1s often carry independent risk factors. American Academy of Ophthalmology NewsNation

USA Today, interviewing several experts, reached a similar bottom line. There isn’t yet enough research to establish definitively that GLP-1s cause NAION or other vision changes. Review of Optometry

So the fair summary is that the signal is real enough for regulators and courts to take seriously, but it isn’t proof.

Where Regulators and Courts Stand Right Now

Body	What it has done	Why it matters to you
US federal court (MDL 3163)	Consolidated NAION cases in E.D. Pa. and is tackling early whether GLP-1 drugs can cause NAION at all.	Early expert rulings could shape every case that follows.
US FDA	Still reviewing the issue through its Sentinel Initiative, with no timeline announced. It doesn’t currently require a warning.	US labels don’t list NAION today.
European Medicines Agency	In June 2025, its safety committee called NAION a very rare semaglutide side effect (up to 1 in 10,000 people) and recommended updating product information.	This is the strongest regulatory finding so far, and it’s specific to semaglutide.
UK MHRA	Updated guidance in February 2026 saying NAION is very rarely reported with semaglutide and treatment should stop if it’s confirmed.	It gives UK patients a clear action step.
Australia’s TGA	Announced broader GLP-1 class warnings in July 2026 covering semaglutide, tirzepatide and dulaglutide.	It signals concern may extend beyond semaglutide.
Drugmakers	Both deny the claims and say they’re monitoring safety data.	Expect a long, contested legal process.

One more point on the FDA’s position. Harvard’s Aaron Kesselheim, who studies FDA regulation, told the Wall Street Journal the agency tends to be conservative about label warnings and wants a credible basis for causation. Slow doesn’t mean dismissive, but it does mean US patients may wait a while for a definitive answer. Review of Optometry

What Should You Do If You’re Taking a GLP-1?

Don’t Panic, and Don’t Quit on Your Own

Doctors quoted in this week’s coverage are consistent on one point. The American Academy of Ophthalmology’s Dr. Raj Maturi says patients on semaglutide who have no symptoms should keep taking it as prescribed and raise any questions with their primary care physician. Stopping a medication that’s controlling your blood sugar or protecting your heart carries its own risks. Review of Optometry

The benefit-risk math also varies by person. Mayo Clinic ophthalmologist Dr. John Chen told the Wall Street Journal that for patients who need these drugs for diabetes or heart disease, the benefits probably outweigh the risk, but the trade-off looks different for someone chasing a small amount of weight loss. That’s a conversation for you and your prescriber, not a headline. Review of Optometry

Act Fast If Your Vision Changes

If you notice sudden blurring, a dark or missing patch, or dimmer colors in one eye, treat it as urgent. Don’t wait for it to clear up overnight. Contact an eye doctor or go to an emergency department the same day. The UK regulator advises urgent ophthalmological assessment for sudden vision loss or rapidly worsening eyesight while on semaglutide. International Business Times

Ask for a Baseline Eye Exam

In 2025, the American Optometric Association began recommending that anyone starting a GLP-1 get an eye exam to check optic nerve health. It’s a sensible, low-cost step, especially if you’re over 50 or have diabetes, hypertension or sleep apnea. Review of Optometry

Questions Worth Bringing to Your Appointment

Do I have any NAION risk factors, such as sleep apnea or high blood pressure?
Should I have a dilated eye exam before or soon after starting?
Given my health goals, do the benefits still clearly outweigh the risks for me?
What should I do, and who should I call, if my vision suddenly changes?

If You’re Considering Fillers or Aesthetic Treatments While on a GLP-1

Many people on GLP-1 medications also start thinking about facial volume, and that’s a big part of why we’re covering this story. If that’s you, two practical points.

First, tell your injector everything you take, including your GLP-1 and any history of eye problems. A good provider wants the full picture.

Second, keep two different issues separate in your mind. The NAION concern discussed here is about the medication. Filler-related vision loss is a separate, rare emergency that can occur when product enters a blood vessel. It calls for the same response, though: if your vision changes during or after any injection, stop and seek emergency care immediately.

The Bottom Line

Patients suing GLP-1 makers over sudden loss of vision are raising a question that regulators abroad already treated as credible enough to act on. The science, meanwhile, isn’t settled, and the risk, where it exists, appears to be small. Those two things can be true at once.

If you’re on a GLP-1, the smart middle path is calm awareness: know the symptoms, understand your own risk factors, get your eyes checked, and keep an open line with your prescriber. We’ll update this post as the FDA review and the court proceedings develop.

This article is for general education and isn’t medical or legal advice. Talk with your physician or eye care provider about your own situation.

Sources and further reading

Considering treatment?

Browse injectors in our directory and compare their training, treatments and location before you book a consultation.

Find a doctor